GLP-1 Receptor Agonists Cost Comparison

Tirzepatide is available under two brand names with different pricing structures: **Mounjaro (diabetes indication):** - List price: approximately $1,086–$1,112 per 4-week supply (all doses) - With commercial insurance savings card: as low as $25/month for eligible patients - Medicare Part D: covered for type 2 diabetes; prior authorization typically required **Zepbound (weight management indication):** - Autoinjector pen list price: approximately $1,086/month - Single-dose vials (2.5 mg, 5 mg) via LillyDirect: $299–$549/month — the most affordable option for patients paying out of pocket - With commercial insurance savings card: as low as $25/month - Medicare Part D: does not cover Zepbound for weight loss; covers for OSA indication starting April 2026 at ~$50/month copay No FDA-approved generic tirzepatide exists as of 2026. Compounded tirzepatide is no longer permitted under the shortage exemption following the FDA's declaration that the shortage has been resolved.

Since Exenatide is brand-only, look for manufacturer patient assistance programs or coupons directly from the drug's maker. Discount cards may offer some savings, but manufacturer programs are often more significant for brand-name medications.

As a brand-name drug with no generic available, Trulicity is expensive. Look for manufacturer savings programs or patient assistance programs to significantly reduce costs.

As Liraglutide is brand-only, manufacturer savings programs or patient assistance programs are often the best way to significantly reduce out-of-pocket costs.

As a brand-name drug, oral semaglutide is very expensive without insurance. Look for manufacturer savings programs or patient assistance programs to help reduce costs.

Semaglutide is available under three brand names with different pricing structures: **Ozempic (injectable, diabetes indication):** - List price: approximately $935–$968 per 4-week supply (all doses) - With Novo Nordisk savings card: as low as $25/month for eligible commercially insured patients - Medicare Part D: covered for type 2 diabetes; prior authorization typically required **Wegovy (injectable, weight management):** - List price: approximately $1,349/month - With Novo Nordisk savings card: as low as $25/month for eligible commercially insured patients - Medicare Part D: covered for weight management (Inflation Reduction Act, 2024) and for cardiovascular risk reduction (SELECT indication); ~$50–$100/month copay typical **Rybelsus (oral tablet):** - List price: approximately $935–$968/month (same as Ozempic) - With Novo Nordisk savings card: as low as $10/month for eligible commercially insured patients - Medicare Part D: covered for type 2 diabetes No FDA-approved generic semaglutide exists as of 2026. Compounded semaglutide is no longer permitted under the shortage exemption following the FDA's declaration that the shortage has been resolved (March 2025 for Ozempic/Wegovy; April 2025 for Rybelsus).